Month: October 2020

32601-86-8, 2-Chloro-3-methylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 21N- (2-Ethy[pheny[)-3-methy[-5-[(3-methy[quinoxa[in-2-y[)amino]- 1 ,2-thiazo[e-4- carboxamide A mixture of 5-amino-N-(2-ethy[pheny[)-3-methy[-1 ,2-thiazo[e-4-carboxamide [Intermediate 11(150 mg, 0.57 mmo[, 1.4 eq), 2-ch[oro-3-methy[quinoxa[ine [CASRN: 32601-86-8] (73 mg, 0.41 mmo[, 1.0 eq) and cesium carbonate (307 mg, 0.94 mmo[, 2.3 eq) in 4 mL dioxane/DMF (7/1) was p[aced in a microwave via[ and f[ushed with argon. Then, pa[[adium(II) acetate (9 mg, 0.04 mmo[, 0.1 eq) andXantphos (24 mg, 0.04 mmo[, 0.1 eq) were added. The via[ was capped and the reaction mixture was stirred at an environmenta[ temperature of 110 C overnight. On coo[ing, the reaction mixture was partitioned between dich[oromethane and water. After fi[tration over Ce[ite, the organic phase was separated and concentrated in vacuo. The crude product was purified via preparative HPLC underacidic conditions (co[umn: Chromatorex C18, e[uent: acetonitri[e/ 0.1% aqueous formic acid 20:80 – 95:5). The product fractions obtained were crysta[[ised from diethy[ether to give 3 mg (1.3% yie[d of theory) of the tit[e compound.UPLC-MS (Method 3): R = 1.48 mm; MS (Elneg) m/z = 402 [M-H].1H-NMR (400 MHz, CDC[3): oe [ppm] = 1.31 (t, 3H), 2.73 (q, 2H), 2.85 (s, 3H), 2.89 (s,3H), 7.21-7.29 (m, 1H, partia[[y covered by so[vent signa[), 7.30-7.39 (m, 2H), 7.58 (t, 1H), 7.64-7.74 (m, 2H), 7.87 (d, 1H), 7.97 (d, 1H), 8.05 (d, 1H), 12.45 (s br, 1H)., 32601-86-8

The synthetic route of 32601-86-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; BAeRFACKER, Lars; PRECHTL, Stefan; SIEMEISTER, Gerhard; WENGNER, Antje Margret; ACKERSTAFF, Jens; NOWAK-REPPEL, Katrin; BADER, Benjamin; LIENAU, Philip; STOeCKIGT, Detlef; WO2014/118186; (2014); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6298-37-9,Quinoxalin-6-amine,as a common compound, the synthetic route is as follows.

6298-37-9, [0143] 5-Chloro-2-methoxybenzoic acid (162.0 mg, 0.868 mmol) was dissolved in DCM (5.0 mL), followed by the addition of catalytic amount of DMF (10 .iL) and oxalyl chloride (0.09 mL, 1.042 mmol) respectively. The reaction was allowed to stir at rt for 30 mm, concentrated in vacuo. The residue was re-dissolved in TIIF (5.0 mL), 2,6-lutidine (0.1 mL, 0.868 mmol) and quinoxalin-6-amine (100.0 mg, 0.689 mmol) were added. The mixture was stirred at rt for 18 hours before silica gel was added to quench the reaction. Solvent was evaporated and the resulting residue was purified via silica gel column chromatography to give 5-chloro-2-methoxy- N-(quinoxalin-6-yl)benzamide (85.0 mg, 39% yield). This compound (35.5 mg, 0.113 mmol) was then mixed with pyridinium chloride (360.0 mg). The mixture was heated to 200 C, stirred for 5 minutes and cooled down to rt. The resulting solid was suspended in water and extracted with EtOAc. The organic phase was separated and evaporated. The resulting residue was purified via preparative TLC to yield 5-chloro-2-hydroxy-N-(quinoxalin-6-yl)benzamide 22(10.6 mg, 31% yield). ?H NIvIR (300 MHz, Acetone-d6) 6 8.89 (dd, J= 14.9, 1.8 Hz, 2H), 8.72 (d, J 2.4 Hz, 1H), 8.26 – 8.07 (m, 3H), 7.10 (d, J = 8.8 Hz, 1H). MS (ESI) exact mass calculated for [M+H] (C15H1 1C1N302) requires mlz 300.1, found mlz 299.8

6298-37-9 Quinoxalin-6-amine 0, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY; JIN, Shengkan; AUGERI, David, J.; KIMBALL, David, S.; LIU, Peng; TAO, Hanlin; ZENG, Xiangang; (82 pag.)WO2016/81599; (2016); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1865-11-8, Methyl quinoxaline-2-carboxylate is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

[1500] a solution of compound 356a (2.5 g, 13.29 mmol) in CH3COOC2H5 (60 ml) was added t-BuOK (1.94 g, 17.28 mmol). The mixture was stirred for 0.25 hour at 25¡ãc. The mixture was quenched with H2O (50 ml). The organic layer was separated and the aqueous was extracted with ea (50 ml x 3). The organic phases were combined, dried with anhydrous Na2SO4, filtered and evaporated. The residue was purified by flash chromatography (pe: ea =20/1 to 10/1) to afford compound 356b (2.45 g, 75.48percent yield) as pale yellow solid. 1H NMR (CDCl3, 400 mhz) delta 9.57 – 9.33 (m, 1h), 8.19 – 8.06 (m, 2h), 7.96 – 7.74 (m, 2h), 4.35 – 4.26 (m, 2h), 4.24 – 4.13 (m, 2h), 1.28 – 1.18 (m, 3h).

1865-11-8, As the paragraph descriping shows that 1865-11-8 is playing an increasingly important role.

Reference£º
Patent; BLADE THERAPEUTICS, INC.; BUCKMAN, Brad, Owen; YUAN, Shendong; ADLER, Marc; EMAYAN, Kumaraswamy; MA, Jingyuang; (687 pag.)WO2018/64119; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

98416-72-9, 6-Bromo-2-chloro-3-methylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

98416-72-9, 4.8 6-Bromo-2-hydrazinyl-3-methylquinoxaline (8) To a solution of compound (5, 0.01 mol) in absolute ethanol (50 mL), hydrazine hydrate 90% (0.015 mol) was added and the reaction mixture was refluxed for 10 h (monitored by TLC). After completion of the reaction, the reaction mixture was filtered, dried and crystallized from methanol to give the product. Yield: 86%; (red-brown powder): mp 129-131 C; IR (KBr) numax in cm-1: 3303, 3253, 3144 (NH2, NH), 2920, 2870 (aliphatic C-H), 1596 (C=N); 1H NMR (DMSO-d6, 500 MHz): delta 2.74 (s, 3H, CH3), 4.51 (s, br s, 2H, NH2; exchangeable with D2O), 7.93-8.27 (m, 3H, Ar-H), 9.02 (s, br s, 1H, NH; exchangeable with D2O); 13C NMR (DMSO-d6, 125 MHz): delta 123.33-140.76 (6Ar-C), 147.84, 148.39 (2C=N); MS (m/z), 237 (M+-CH3; 100%), 252 (M+; 40%), 253 (M++1; 10%), 254 (M++2; 38%). Anal. Calcd for C9H9BrN3 (253.10): C, 42.71; H, 3.58; N, 22.14. Found: C, 42.97; H, 3.44; N, 22.32.

The synthetic route of 98416-72-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Abbas, Hebat-Allah S.; Al-Marhabi, Aisha R.; Eissa, Sally I.; Ammar, Yousry A.; Bioorganic and Medicinal Chemistry; vol. 23; 20; (2015); p. 6560 – 6572;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.

(IB) Method B: A suspension of ethyl 3-chloroquinoxaline-2-carboxylate (11.5 g, 48.6 mmol) prepared by a method recited in J. Chem. Soc. 1945, 622, trimethylboroxine (6.06 g, 48.6 mmol),[l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.98 g, 2.42 mmol), and potassium carbonate (13.4 g, 97.0 mmol) in 1,4-dioxane (162 mL) was heated for 4.5 hour at 115 C. After being cooled to ambient temperature, the reaction mixture was filtrated through celite with ethyl acetate (500 mL). The filtrate was combined and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane:ethyl acetate = 9:1 to 2:1) followed by recrystallization from ethanol-water (1/4) to give ethyl 3-methylquinoxaline-2-carboxylate as a colorless crystals (8.36 g, 80%). mp 74-75 0C. MS (APCI): m/z 217 (M+H).

49679-45-0, As the paragraph descriping shows that 49679-45-0 is playing an increasingly important role.

Reference£º
Patent; MITSUBISHI TANABE PHARMA CORPORATION; MORIMOTO, Hiroshi; SAKAMOTO, Toshiaki; HIMIYAMA, Toshiyuki; KAWANISHI, Eiji; MATSUMURA, Takehiko; WO2010/30027; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

General Method 6: Preparation of (2-((3-chlorophenoxy)methyl)piperidin-1-yl)(3-hydroxyquinoxalin-2-yl)methanone (6-5); Step 1: A suspension of 3-hydroxy-2-quinoxaline carboxylic acid 6-1 (1.0 g, 5.26 mmol), thionyl chloride (4.6 mL, 63.1 mmol, 12.0 equiv) and catalytic DMF (50 muL) in 10 mL toluene was heated to 80 C. After 1 h of heating, the reaction mixture was cooled to room temperature and evaporated to dryness to yield 6-2. In a separate flask, 2-piperidine methanol (0.61 g, 5.26 mmol) and triethylamine (0.88 mL, 6.3 mmol, 1.2 equiv) in 10 mL CH2Cl2 was cooled to 0 C. To this mixture was added 6-2 dropwise. The reaction was allowed to stir at room temperature for 1 h after which was diluted with H2O (10 mL), extracted with CH2Cl2 (2¡Á10 mL), dried over Na2SO4 and evaporated to dryness. The crude product was purified by flash chromatography (20-40% EtOAc/hexanes) to produce compound 6-3., 1204-75-7

1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; CHENG, CLIFFORD; SHIPPS, JR., GERALD W.; HUANG, XIAOHUA; HUANG, YING; SHAO, NING; RAO, ASHWIN; PALANI, ANANDAN; ORTH, PETER; VOIGT, JOHANNES H.; HERR, ROBERT J.; ROSSITER, LANA MICHELE; ZENG, QI; SUN, XIANFENG; US2012/122837; (2012); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

34117-90-3, 3-Chloroquinoxalin-2-amine is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 2; 3-Pyridinemethanol (487 muL, 5.01 mmol) was dissolved in tetrahydrofuran (6.0 mL). To this, 60% sodium hydride (in oil) (200 mg, 5.01 mmol) was added under a nitrogen atmosphere at 0 C. and the mixture was stirred at the same temperature for 15 minutes. To this, 2-amino-3-chloroquinoxaline (300 mg, 1.67 mmol) was added and the mixture was stirred at room temperature for 14 hours. Then, a saturated aqueous ammonium chloride solution was added to the reaction mixture, and extraction with ethyl acetate was performed, followed by washing with brine and drying over anhydrous sodium sulfate. The solvent was evaporated off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform/methanol=9/1). Further, slurry purification was performed using diisopropyl ether, to give 2-amino-3-[(pyridin-3-yl)methoxy]quinoxaline (Compound BA) (383 mg, yield: 91%).ESIMS m/z: 443 (M+H)+; 1H-NMR (300 MHz, CDCl3, delta): 5.20 (br s, 2H), 5.61 (s, 2H), 7.32-7.48 (m, 3H), 7.62 (dd, J=1.5, 8.1 Hz, 1H), 7.72 (dd, J=1.5, 8.1 Hz, 1H), 7.84-7.87 (m, 1H), 8.62 (dd, J=1.5, 4.8 Hz, 1H), 8.80 (d, J=2.2 Hz, 1H), 8.35 (s, 1H)., 34117-90-3

The synthetic route of 34117-90-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Amishiro, Nobuyoshi; Fukuda, Yuichi; Kinpara, Keisuke; Mie, Motoya; Tagaya, Hisashi; Takahashi, Takeshi; US2011/237584; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1210048-05-7,7-Bromo-5-fluoroquinoxaline,as a common compound, the synthetic route is as follows.

Under an argon atmosphere, 750 mg (0.819 mmol) of tris-(dibenzylidene-acetone)-dipalladium(0) and 551 mg (1.966 mmol) of tricyclohexylphosphine were dissolved in 80 ml dioxane. |814 mg – -(15.019 mmol) of 4,4,414’5,5,5’5′-octamethyl-2,2t-bi-l,3,2-dioxaborolan, 3100 mg (13.654 mmol) of the compound from example 9OA and 2010 mg (20.4813 mmol) potassium acetate were added and the mixture was stirred overnight at 800C. After cooling, dioxane was added to the reaction mixture and it was filtered on Celite. The filtrate was concentrated in a rotary evaporator at reduced pressure and dried under high vacuum. We obtained 7.08 g of the raw product (purity 69% according to GC-MS), which was reacted further without further purification.GC-MS (method 6): R, = 6.78 min; MS (EIpos): m/z = 274 [M]+., 1210048-05-7

1210048-05-7 7-Bromo-5-fluoroquinoxaline 59286334, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT; BAeRFACKER, Lars; KAST, Raimund; GRIEBENOW, Nils; MEIER, Heinrich; KOLKHOF, Peter; ALBRECHT-KUePPER, Barbara; NITSCHE, Adam; STASCH, Johannes-Peter; SCHNEIDER, Dirk; TEUSCH, Nicole; RUDOLPH, Joachim; WHELAN, James; BULLOCK, William; PLEASIC-WILLIAMS, Susan; WO2010/20363; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

A degassed mixture of the crude 3-(3-pyrrolidin-1-yl-prop-1-ynyl)-2-trimethylstannanyl-imidazo[1,2-a]pyridine-6-carboxylic acid bis-(3-methyl-butyl)amide (ca. 262 mg) and 6-bromoquinoxaline (96 mg) in DMF (3 ml) was treated with Pd(PPh3)4 (48 mg). The reaction mixture was transferred to a pre-heated oil bath (110C) and stirred in a sealed tube at this temperature for 18 h. The mixture was diluted with diethyl ether (25 ml) and washed with water (1 x 20 ml). The aqueous layer was extracted with diethyl ether (2 x 15 ml). The combined organic extracts were washed with brine (30 ml), dried over sodium sulfate, filtered, and evaporated. The crude product was isolated by column chromatography and re-purified by preparative HPLC-MS., 50998-17-9

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; Santhera Pharmaceuticals (Schweiz) AG; EP2168965; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

6344-72-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6344-72-5,6-Methylquinoxaline,as a common compound, the synthetic route is as follows.

EXAMPLE 1 Catalytic Air Dehydrogenation of 6-Hydroxymethyl-methyl-quinoxaline With 5% Pd/C In a 500 ml flask, 6-methyl-quinoxaline (10 g, 69.4 mmol) was dissolved together with N-chlorosuccinimide (14 g, 105.3 mmol) and benzoyl peroxide (0.4 g, 1.65 mmol) in 240 g of acetonitrile. The flask was connected to a reflux-condenser and the solution was refluxed for 6 hours followed by another addition of 0.1 g of benzoyl peroxide. Reflux continued for a total reaction time of 12 hours. The solution was then analyzed showing the formation of 6-chloromethyl-quinoxaline (80% selectivity and 60% conversion according to GC analysis).

The synthetic route of 6344-72-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Air Products and Chemicals, Inc.; US6559308; (2003); B1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider